Michael Makris: NovoNordisk Has Applied to the FDA for Approval of Mim8
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, UK. Editor-in-Chief of Research and Practice in Thrombosis and Haemostasis, shared on LinkedIn:
‘‘NovoNordisk has applied to the FDA for approval of Mim8, a bispecific antibody which will be a direct competitor to emicizumab (Hemlibra).
The data we have seen presented at scientific meetings and published are strong, and suggest that approval is likely to be given.”
Read the full article here.
Article: Novo Nordisk submits Biologics License Application (BLA) to FDA for Mim8; an investigational, prophylaxis treatment for people living with hemophilia A with or without inhibitors
Stay updated on the emerging in the field of Hemophilia with Hemostasis Today.
-
Jul 3, 2026, 23:08For Jatinder Minhas, The Strength of Simulation Training Is Learning Together Across Disciplines – ESO
-
Jul 3, 2026, 22:47Khaled Musallam: Caring for Women with Thalassemia From Puberty to Pregnancy and Beyond
-
Jul 3, 2026, 21:25Matteo Foschi: Happy to Join the Italian Stroke Association Summer School
-
Jul 3, 2026, 20:39Maha Othman: Excited to Present on PPH for The Lancet Haematology Commission on Global Female Health
-
Jul 3, 2026, 19:15Edward Lee Carter: Anticoagulation Drift – The Patient Changes, the Plan Should Too
-
Jul 3, 2026, 19:15Marcelo Soares: Cytokine and Lymphocyte Profiles of Cancer Patients With COVID-19
-
Jul 3, 2026, 19:13Anwar Elshikh: Calciphylaxis and Skin Issues in Renal Failure Patients
-
Jul 3, 2026, 19:11Amr M. Fahmi: Genotype-Guided Warfarin Dosing in the Arab Population
-
Jul 3, 2026, 19:10Isabella Presch: A Step Toward Greater Regulatory Clarity in Genome-Editing Therapeutics